![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Mylan Laboratories Limited Hyderabad In, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Escitalopram oxalate, Process II, supported by a 'Valid' Certificate of Suitability (CEP) with the number R0-CEP 2019-130 - Rev 01
This Chemical Type CEP, issued on July 13, 2023, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 2733 associated with this CEP further emphasizes